For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Celgene Avilomics Research, Inc.

USPTO Granted Patents = 44

CIPO Patents = 4

EPO Patents = 2

Forward Citations = 895

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Juswinder Singh (31 out of 68 patents)

Russell Colyn Petter (31 out of 81 patents)

Deqiang Niu (25 out of 83 patents)

4. Arthur F Kluge (20 out of 95 patents)

5. Richland Wayne Tester (19 out of 30 patents)

6. Lixin Qiao (18 out of 40 patents)

7. Shomir Ghosh (11 out of 70 patents)

8. William Frederick Westlin, Iii (9 out of 15 patents)

9. Hormoz Mazdiyasni (8 out of 19 patents)

10. Zhendong Zhu (8 out of 20 patents)

11. Kwangho Lee (7 out of 27 patents)

12. Mei Lai (4 out of 16 patents)

13. Matthew Frank Baevsky (4 out of 9 patents)

14. Steven Richard Witowski (4 out of 10 patents)

15. Lisa Beebe (3 out of 4 patents)

Core Competencies:

ERK Inhibitors

Protein Kinase Conjugates

Heteroaryl Compounds

Epidermal Growth Factor Receptor Kinase

Bruton'S Tyrosine Kinase

MK2 Inhibitors

HCV Protease Inhibitors

Mutant-Selective EGFR Inhibitors

Pyrimidine Compounds

Substituted Pyrimidines

Heterocyclic Compounds

Diaminopyrimidines

44 patents: Sort by Forward Citations

1. 9561228 - ERK inhibitors and uses thereof (2017-02-07),

2. 9556426 - Protein kinase conjugates and inhibitors (2017-01-31),

3. 9549927 - Heteroaryl compounds and uses thereof (2017-01-24),

4. 9540335 - Salts of an epidermal growth factor receptor kinase inhibitor (2017-01-10),

5. 9539255 - Solid forms of an epidermal growth factor receptor kinase inhibitor (2017-01-10),

6. 9504686 - ERK inhibitors and uses thereof (2016-11-29),

7. 9492471 - Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase (2016-11-15),

8. 9458175 - MK2 inhibitors and uses thereof (2016-10-04),

9. 9422333 - HCV protease inhibitors and uses thereof (2016-08-23),

10. 9415049 - Heteroaryl compounds and uses thereof (2016-08-16),

11. 9409921 - 2,4-disubstituted pyrimidines as kinase inhibitors (2016-08-09),

12. 9409887 - Mutant-selective EGFR inhibitors and uses thereof (2016-08-09),

13. 9393246 - 4,6-disubstituted pyrimidines as kinase inhibitors (2016-07-19),

14. 9375431 - 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors (2016-06-28),

15. 9364476 - Methods of treating a Bruton's Tyrosine Kinase disease or disorder (2016-06-14),

Celgene Avilomics Research, Inc. is a leading biotechnology company focused on innovative drug discovery and development. They specialize in developing precision medicines using Avilomics, a proprietary platform that integrates advanced genomics and computational biology. With a mission to improve patients' lives, Celgene Avilomics Research is dedicated to bringing breakthrough therapies to individuals suffering from various diseases, including cancer, inflammatory disorders, and immune-mediated conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

44 Patents

#51 in Cambridge, MA

#443 in Massachusetts

#7,673 in US

#15,285 in the World

Cambridge, MA, United States of America

Celgene Avilomics Research, Inc.

Forward Citations = 895

41 inventors:

Juswinder Singh (31 out of 68 patents)

Russell Colyn Petter (31 out of 81 patents)

Deqiang Niu (25 out of 83 patents)

4. Arthur F Kluge (20 out of 95 patents)

5. Richland Wayne Tester (19 out of 30 patents)

Please report any incorrect information to support@idiyas.com

Loading…